PGO Stock Overview
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Prostatype Genomics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.0016 |
| 52 Week High | kr0.036 |
| 52 Week Low | kr0.0016 |
| Beta | 0.69 |
| 11 Month Change | -60.00% |
| 3 Month Change | -66.67% |
| 1 Year Change | -94.29% |
| 33 Year Change | -99.88% |
| 5 Year Change | n/a |
| Change since IPO | -99.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| PGO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 0.09% |
| 1Y | -94.3% | -19.3% | 3.1% |
Return vs Industry: PGO underperformed the German Biotechs industry which returned -19.3% over the past year.
Return vs Market: PGO underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| PGO volatility | |
|---|---|
| PGO Average Weekly Movement | 31.1% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: PGO's share price has been volatile over the past 3 months.
Volatility Over Time: PGO's weekly volatility (31%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 6 | Fredrik Rickman | www.prostatypegenomics.com |
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company’s test is based on database containing prostate cancer patients, as well as provides decision support for patients and doctors when making a treatment decision.
Prostatype Genomics AB (publ) Fundamentals Summary
| PGO fundamental statistics | |
|---|---|
| Market cap | €2.16m |
| Earnings (TTM) | -€3.68m |
| Revenue (TTM) | €331.52k |
6.5x
P/S Ratio-0.6x
P/E RatioIs PGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGO income statement (TTM) | |
|---|---|
| Revenue | kr3.73m |
| Cost of Revenue | kr19.45m |
| Gross Profit | -kr15.72m |
| Other Expenses | kr25.72m |
| Earnings | -kr41.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.042 |
| Gross Margin | -421.62% |
| Net Profit Margin | -1,111.45% |
| Debt/Equity Ratio | 47.3% |
How did PGO perform over the long term?
See historical performance and comparison